BR112022024476A2 - 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8 - Google Patents

5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8

Info

Publication number
BR112022024476A2
BR112022024476A2 BR112022024476A BR112022024476A BR112022024476A2 BR 112022024476 A2 BR112022024476 A2 BR 112022024476A2 BR 112022024476 A BR112022024476 A BR 112022024476A BR 112022024476 A BR112022024476 A BR 112022024476A BR 112022024476 A2 BR112022024476 A2 BR 112022024476A2
Authority
BR
Brazil
Prior art keywords
disorders
inhibitors
oxopyrrolidino
carboxamide
useful
Prior art date
Application number
BR112022024476A
Other languages
English (en)
Inventor
Arasappan Ashok
M Bell Ian
M Cox Jason
J Kelly Michael Iii
E Layton Mark
Liu Hong
Liu Jian
A Shah Akshay
D Vanheyst Michael
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of BR112022024476A2 publication Critical patent/BR112022024476A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

5-OXOPIRROLIDINO-3-CARBOXAMIDAS COMO INIBIDORES DE NAV1.8. Novos compostos da fórmula estrutural (I) e os sais dos mesmos farmaceuticamente aceitáveis, são inibidores da atividade do canal Nav1.8 e podem ser úteis no tratamento, prevenção, manuseio, melhora, controle e supressão de doenças mediadas pela atividade do canal Nav1.8. Os compostos da presente invenção podem ser úteis no tratamento, prevenção ou manuseio de distúrbios de dor, distúrbios de tosse, distúrbios de coceira aguda e distúrbios de coceira crônica.
BR112022024476A 2020-06-17 2021-06-14 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8 BR112022024476A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040465P 2020-06-17 2020-06-17
PCT/US2021/037160 WO2021257420A1 (en) 2020-06-17 2021-06-14 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors

Publications (1)

Publication Number Publication Date
BR112022024476A2 true BR112022024476A2 (pt) 2022-12-27

Family

ID=79268285

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024476A BR112022024476A2 (pt) 2020-06-17 2021-06-14 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8

Country Status (10)

Country Link
US (1) US20230227405A1 (pt)
EP (1) EP4167993A1 (pt)
JP (1) JP2023530320A (pt)
KR (1) KR20230026405A (pt)
CN (1) CN115697327A (pt)
AU (1) AU2021292062A1 (pt)
BR (1) BR112022024476A2 (pt)
CA (1) CA3180372A1 (pt)
MX (1) MX2022015580A (pt)
WO (1) WO2021257420A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308215A (en) * 2021-05-07 2024-01-01 Merck Sharp & Dohme Llc Cycloalkyl 3-Oxopyrazine Carboxamides and Cycloheteroalkyl 3-Oxopyrazine Carboxamides as NAV1.8 Inhibitors
AU2022286438A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
AU2022285758A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
CN117813302A (zh) 2021-06-04 2024-04-02 沃泰克斯药物股份有限公司 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂
JP2024520643A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン
BR112023025264A2 (pt) 2021-06-04 2024-02-20 Vertex Pharma Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels

Also Published As

Publication number Publication date
AU2021292062A1 (en) 2023-01-19
US20230227405A1 (en) 2023-07-20
EP4167993A1 (en) 2023-04-26
CA3180372A1 (en) 2021-12-23
CN115697327A (zh) 2023-02-03
WO2021257420A1 (en) 2021-12-23
MX2022015580A (es) 2023-01-24
KR20230026405A (ko) 2023-02-24
JP2023530320A (ja) 2023-07-14

Similar Documents

Publication Publication Date Title
BR112022024476A2 (pt) 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8
BR112022024450A2 (pt) 2-oxo-oxazolidina-5-carboxamidas como inibidores de nav1.8
BR112021008524A8 (pt) 2-amino-n-heteroaril-nicotinamidas como inibidores de nav 1.8
BR112022025805A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir um distúrbio, condição ou doença
BR112023023186A2 (pt) 3-oxopiperazina carboxamidas de arila e 3-oxopiperazina carboxamidas de heteroarla como inibidores de nav1.8
BR112022026899A2 (pt) Composto representado pela fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método de tratamento ou prevenção de uma infecção por vírus, método de inibição da protease 3c viral ou protease 3cl viral em um mamífero e método de tratamento de um distúrbio respiratório
BR112023023239A2 (pt) Carboxamidas de cicloalquil 3-oxopiperazina e carboxamidas de cicloheteroalquil 3-oxopiperazina como inibidores de nav1.8
MY196455A (en) Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection
MX2023007192A (es) Inhibidores de prmt5.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
BR112023002573A2 (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de infecção viral e distúrbio respiratório e método de inibição de protease viral
MX2022012714A (es) Inhibidores de la replicacion de norovirus y coronavirus.
BR112022022535A2 (pt) Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk
BR112021020247A2 (pt) Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112022014861A2 (pt) Métodos de tratamento para deficiência de alfa-1 antittripsina
BR112023000142A2 (pt) Derivados de benzodiazepina úteis no tratamento de infecção pelo vírus sincicial respiratório
BR112018076766A2 (pt) derivados de prolinamida alifática
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
EA202193211A1 (ru) Лечение синуклеопатий
BR112022019245A2 (pt) Inibidores de catepsina para prevenir ou tratar infecções virais
WO2019066548A3 (ko) 심부전의 예방 또는 치료용 약학적 조성물
WO2023230348A3 (en) Dosage regimens for treatment of dengue infection
WO2016178987A3 (en) Preventing or treating viral infection by inhibition of the histone methyltransferase ezh1 or ezh2